Brit J Heamatol: Serum BDNF concentration seisprediction of multiple neuropathy and total survival in patients with multiple myeloma
-
Last Update: 2020-07-12
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Brain-derived neurotrophic factor (BDNF) is a protein that has multiple effects on neurons andvascularfunctionHowever, its prognosis and function in multiple myeloma (MM) are still unknown, researchers investigated the effects of BDNF on the risk and clinical outcomeofofe of peripheral neuropathy (CIPN) caused by chemotherapy, in a study published in the journal British Journal of Blood System DiseasesThe team included 91 patients who underwent newdiagnosisMM who received chemotherapy based on bolyzomi and/or thalidomideThe researchers used ELISA to test for BDNF in the serumMultiple neuropathy was evaluated in accordance with CTCAE standard v5the researchers observed a correlation between BDNF concentrations and the severity of multiple neuropathy (P-0.0463)Patients who responded to treatment had a high BDNF level (P-0.0326) and it was shown that BDNF was a useful marker for predicting a lack of response after eight treatment cycles (sensitivity was -100%, specificity was -61.5%, P-0.0142)In addition, the marker has significant diagnostic value in the diagnosis of CIPN (sensitivity is -76%, specificity is -71.43%; Low BDNF levels are independent adverse prognosis factors associated with total lifetime (OS) reduction (risk ratio (HR) s 2.79, P -0.0470)in general, BDNF levels may have a prognostic effect in predicting CIPN in MM patients and are a useful biomarker
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
